Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura

On behalf of the Nine-i Investigators

Research output: Contribution to journalArticlepeer-review

49 Scopus citations


Thrombotic thrombocytopenic purpura (TTP) is fatal in 90% of patients if left untreated and must be diagnosed early to optimize patient outcomes. However, the very low incidence of TTP is an obstacle to the development of evidence-based clinical practice recommendations, and the very wide variability in survival rates across centers may be partly ascribable to differences in management strategies due to insufficient guidance. We therefore developed an expert statement to provide trustworthy guidance about the management of critically ill patients with TTP. As strong evidence was difficult to find in the literature, consensus building among experts could not be reported for most of the items. This expert statement is timely given the recent advances in the treatment of TTP, such as the use of rituximab and of the recently licensed drug caplacizumab, whose benefits will be maximized if the other components of the management strategy follow a standardized pattern. Finally, unanswered questions are identified as topics of future research on TTP.

Original languageEnglish (US)
Pages (from-to)1518-1539
Number of pages22
JournalIntensive Care Medicine
Issue number11
StatePublished - Nov 1 2019

All Science Journal Classification (ASJC) codes

  • Critical Care and Intensive Care Medicine


Dive into the research topics of 'Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura'. Together they form a unique fingerprint.

Cite this